On February 9, Shaoxing Keqiao Economic and Technological Development Zone Leaders Conference was held in Jin Keqiao Science and Technology City. Keqiao Management Committee honored various entities and individuals with outstanding performance in various fields in the year of 2024.

Leadingtac was awarded the “2024 Jinkai High-Quality Entrepreneurship Award” for its excellent R&D results in the field of targeted protein degradation. Dr. Yan Feng, General Manager of Leadingtac, was invited to attend the meeting and receive the award on the stage.

About Us:

Leadingtac is a leading company in the field of PROTAC drug discovery and development in China. Founded at the end of 2019, Leadingtac has established R&D centers in Zhangjiang, Pudong, Shanghai and Keqiao, Shaoxing, Zhejiang. The company's R&D direction focuses on Target Protein Degradation, and has independently developed SPUD® (Specific Protein Ubiquitination and Degradation), which can efficiently and rapidly screen for proteasomal degradation, new E3 ligand screening, and lysosomal degradation. Ubiquitination and Degradation) technology platform:

Nano-SPUD® for Target Proteins

Nano-SPUD® for E3 Ligases

Lyso-SPUD® for Lysosome

Based on this platform, Leadingtac has independently developed its first pipeline of IRAK4 degraders, LT-002, for the treatment of autoimmune diseases, which has a huge market potential and has been approved by the CDE and FDA to enter clinical trials in China and the United States, and is the first in the country and the second in the world in terms of research and development progress.

Leadingtac's follow-on pipeline includes the JAK-STAT pathway, KRAS and other difficult-to-adhere-to targets for the treatment of autoimmune diseases, as well as solid tumors such as lung, pancreatic, and colorectal cancers, all of which are also leading the world in terms of R&D progress.